Drugs that contain Solifenacin Succinate
1. Vesicare patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6017927 | ASTELLAS | Quinuclidine derivatives and medicinal composition thereof |
Nov, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6017927 (Pediatric) | ASTELLAS | Quinuclidine derivatives and medicinal composition thereof |
May, 2019
(4 years ago) | |
Market Authorisation Date: 19 November, 2004
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of VESICARE before it's drug patent expiration?
More Information on Dosage
VESICARE family patents
2. Vesicare Ls patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9918970 | ASTELLAS | Pharmaceutical composition comprising solifenacin |
May, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Nov 26, 2023 |
| New Product(NP) | May 26, 2023 |
| W(W) | Nov 26, 2023 |
Market Authorisation Date: 26 May, 2020
Treatment: NA
Dosage: SUSPENSION;ORAL
How can I launch a generic of VESICARE LS before it's drug patent expiration?
More Information on Dosage
VESICARE LS family patents